Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Xeris Biopharma Holdings (XERS) Amortization - Intangibles (2021 - 2025)

Xeris Biopharma Holdings' Amortization - Intangibles history spans 5 years, with the latest figure at $2.7 million for Q4 2025.

  • For the quarter ending Q4 2025, Amortization - Intangibles changed 0.0% year-over-year to $2.7 million, compared with a TTM value of $10.8 million through Dec 2025, changed 0.0%, and an annual FY2025 reading of $10.8 million, changed 0.0% over the prior year.
  • Amortization - Intangibles for Q4 2025 was $2.7 million at Xeris Biopharma Holdings, roughly flat from $2.7 million in the prior quarter.
  • The five-year high for Amortization - Intangibles was $2.7 million in Q1 2022, with the low at $550000.0 in Q4 2021.
  • Average Amortization - Intangibles over 5 years is $2.6 million, with a median of $2.7 million recorded in 2022.
  • Year-over-year, Amortization - Intangibles soared 392.91% in 2022 and then decreased 0.04% in 2025.
  • Tracing XERS's Amortization - Intangibles over 5 years: stood at $550000.0 in 2021, then surged by 392.91% to $2.7 million in 2022, then changed by 0.0% to $2.7 million in 2023, then changed by 0.0% to $2.7 million in 2024, then changed by 0.0% to $2.7 million in 2025.
  • Per Business Quant, the three most recent readings for XERS's Amortization - Intangibles are $2.7 million (Q4 2025), $2.7 million (Q3 2025), and $2.7 million (Q2 2025).